IGC Pharma, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine months ended September 30, | ||||
|---|---|---|---|---|
| 2026 ($) | 2025 ($) | |||
| Cash flows from operating activities: | ||||
| Net loss | (7,384) | (4,618) | ||
| Adjustment to reconcile net loss to net cash: | ||||
| Depreciation and amortization | 172 | 414 | ||
| Impairment of assets | - | 152 | ||
| Stock-based compensation and expenses, net | 2,146 | 1,637 | ||
| Other items | 328 | (1,077) | ||
| Changes in: | ||||
| Accounts receivable, net | (55) | (5) | ||
| Inventory | (3) | 90 | ||
| Deposits and advances | 18 | 223 | ||
| Claims and advances | 16 | 8 | ||
| Accounts payable | 647 | (207) | ||
| Accrued and other liabilities | 116 | (953) | ||
| Operating lease asset | 11 | 116 | ||
| Operating lease liability | (2) | (7) | ||
| Net cash used in operating activities | (3,990) | (4,227) | ||
| Cash flow from investing activities: | ||||
| Purchase of property, plant, and equipment | (6) | (55) | ||
| Sale of property, plant, and equipment | - | 703 | ||
| Investment in marketable securities | - | (25) | ||
| Acquisition and development of intangible assets | (611) | (559) | ||
| Net cash (used in) provided by investing activities | (617) | 64 | ||
| Cash flows from financing activities: | ||||
| Net proceeds from the issuance of common stock | 3,104 | 4,768 | ||
| Net proceeds from the loan | 1,005 | (2) | ||
| Net cash provided by financing activities | 4,109 | 4,766 | ||
| Effects of exchange rate changes on cash and cash equivalents | (25) | 32 | ||
| Net (decrease)/ increase in cash and cash equivalents | (523) | 635 | ||
| Cash and cash equivalents at the beginning of the period | 900 | 470 | ||
| Cash and cash equivalents at the end of the period | 377 | 1,105 | ||
| Supplementary information: | ||||
| Cash paid for interest | 92 | 4 | ||
| Other item: | ||||
| Unrealized loss from current investment | 3 | - | ||
| Amortization of debt discount and issuance cost | 189 | - | ||
| Net change in fair value of derivative liability (gain) | (40) | - | ||
| Profit/Loss on sale of fixed assets, net | (1,090) | |||
| Provision for bad debt | 13 | |||
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Settlement of the following due to executive officers through common stock subscriptions (Note 11 and Note 13): | ||||
| Compensation payable during the period (Other item) | 176 | - | ||
| Compensation | 423 | - | ||
| Loans | 555 | - | ||
| September 30, 2026, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.